| Document |
Document Title |
|
WO/2024/152855A1 |
A pyridazinone compound as shown in formula (I), and a preparation method therefor, and a pharmaceutical composition and the use thereof. The compound, as a PARP inhibitor, has potential advantages in terms of blood-brain barrier permeab...
|
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/147009A1 |
One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is NH and Y is CO ring C is a 6-membered heteroaryl or aryl group, or a partially or fully unsaturated 6-member...
|
|
WO/2024/146559A1 |
Disclosed in the present invention are a pyridazinone heterocyclic compound shown in formula (I), a stereoisomer, a deuterated substance, a solvate, a pharmaceutically acceptable salt or an eutectic crystal thereof, a pharmaceutical comp...
|
|
WO/2024/140595A1 |
Disclosed in the present invention are a tricyclic compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention is a compound as represented by formula (I) or a pharmaceutically acc...
|
|
WO/2024/143336A1 |
In the present invention, a compound represent by formula Z-I has excellent bactericidal activity and has excellent stability. (In the formula: Q1 represents a phenyl group, or the like; Q2 represents a phenyl group, or the like; partial...
|
|
WO/2024/140824A1 |
A pyridazine compound represented by formula (I), a pharmaceutical composition, and a preparation method therefor and a use thereof. The compound has a good NLRP3 inhibitory effect, can be used alone or in combination with other drugs to...
|
|
WO/2024/141534A1 |
The specification generally relates to crystalline forms of inhibitors of the NLRP3 inflammasome, pharmaceutical compositions comprising such crystalline forms, chemical processes useful for the preparation of inhibitors of the NLRP3 inf...
|
|
WO/2024/131935A1 |
The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but ar...
|
|
WO/2024/132895A1 |
A compound of Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2024/137981A1 |
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, RB, Rc, n, and p are as defined herein. Also provided are pharmaceutically acceptable compositions comprising a compound of ...
|
|
WO/2024/130344A1 |
The present invention relates to methods and uses of preventing or treating cancer The method or use may comprise administration of a cancer therapy together with a compound of Formula (I). In the compound of Formula (I) A is a substitut...
|
|
WO/2024/130342A1 |
The present invention relates to compounds, pharmaceutical compositions of said compounds, and uses of said compounds, especially for inhibition of Transient Receptor Potential channel family, Vanilloid subfamily member 6 (TRPV6). The co...
|
|
WO/2024/132901A1 |
A compound of formula (I) wherein R1, R2, and G are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2024/130689A1 |
Disclosed are a 2-fluorobiphenyl-4-acetic acid derivative, a preparation method therefor, and use thereof. The structural formula of the 2-fluorobiphenyl-4-acetic acid derivative is set forth in formula I. The compound can be prepared by...
|
|
WO/2024/124287A1 |
The present invention relates generally to a compound and/or a composition comprising the compound, useful for the treatment of, or prevention of, a Coronavirus (CoV) infection in particular SARS-CoV/SARS-CoV-1 or SARS-CoV-2.
|
|
WO/2024/121013A1 |
The present invention provides new derivatives having the general formula (I), (I) wherein R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, and X5 are as defined herein, compositions including the compounds, processes of manufacturing the com...
|
|
WO/2024/114635A1 |
The present disclosure belongs to the field of medicinal chemistry; and relates to a dihydrophthalazine-containing compound, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the treatmen...
|
|
WO/2024/109922A1 |
Disclosed are a bridged ring pyridazine compound and the use thereof, which compound and use belong to the technical field of chemical medicine. Provided is a bridged ring pyridazine compound as represented by formula I, which compound c...
|
|
WO/2024/104345A1 |
Provided are a pyridazinone derivative and use thereof. The pyridazinone derivative is represented by general formula (I). The compound of general formula (I) has activity on various fungal diseases and bacterial diseases in the agricult...
|
|
WO/2024/106438A1 |
The present invention provides a superior novel pest control agent for agriculture and horticulture. The present invention pertains to: compounds represented by general formula [I] (each symbol is as described in the description) or salt...
|
|
WO/2024/100545A1 |
The present invention proposes novel derivatives of phthalazinium dicyanomethanides (I), a process for manufacturing same, and the use thereof in the functionalization of peptides and proteins, in the attachment of biological polymers to...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
|
WO/2024/084491A1 |
The present invention discloses a process for synthesis of Res metirom and its intermediates thereof. More particularly, the invention discloses process for synthesis of a key intermediate, 6-(4-amino, 2,6-dichlorophenoxy)4- isopropylpyr...
|
|
WO/2024/083257A1 |
Provided in the present invention are an SOS1 protein degradation agent and a use thereof. Specifically, provided in the present invention is a formula (I) for a S-L-E compound, and a stereoisomer, enantiomer, diastereomer, deuterated co...
|
|
WO/2024/086361A1 |
Described herein are molecular glue degrader compounds that bind to both a target protein and a RING E3 Ubiquitin Ligase, as well as related compositions and methods of use, e.g., for degradation of the target protein and/or the treatmen...
|
|
WO/2024/079733A1 |
The present invention provides a process for the preparation of aminopyridazine derivatives, and novel pyridazine-based and pyrazole-based compounds which are useful as either starting materials or intermediates in said process.
|
|
WO/2024/079072A1 |
The present invention relates to a compound of formula (I) or any of its acceptable salts (I) wherein W, X, Y and Z each independently represents =CH- or -N=, provided that at most two of W, X, Y and Z both represent a -N= group, R1 repr...
|
|
WO/2024/067676A1 |
Provided are a compound represented by general formula (1), a preparation method therefor, and use of the compound represented by general formula (1) and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates the...
|
|
WO/2024/040350A1 |
The present disclosure relates to pyridazinone compound of the Formula (I) for the treatment of respiratory diseases, such as, chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, Long QT syndrome or Dravet syndrome, wh...
|
|
WO/2024/037558A1 |
The present invention relates to novel forms of Compound I, preparation thereof, pharmaceutical composition containing the same and use thereof, wherein, the compound is (S) -5- ( (1- (3- (5-methyl-3- (trifluoromethyl) -8, 9-dihydropyrid...
|
|
WO/2024/028782A1 |
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relat...
|
|
WO/2024/022186A1 |
The present invention relates to a methylpyrazole compound, a pharmaceutical composition comprising same, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by formula (...
|
|
WO/2024/008176A1 |
A nitrogen-containing heterocyclic compound represented by formula (I-a), or a stereoisomer, a deuterated compound, a solvate, a pharmaceutically acceptable salt or a eutectic crystal thereof, a pharmaceutical composition comprising same...
|
|
WO/2024/010963A1 |
The present disclosure provides phosphonate-containing heterocycle compounds with TYK2/JAK1 inhibitory activities, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Fo...
|
|
WO/2024/002318A1 |
The present invention relates to the technical field of medicines, and in particular to a pyridazopyridone derivative used as an SOS1 protein inhibitor and a use thereof. The provided compound has an obvious inhibition effect on the acti...
|
|
WO/2024/002375A1 |
Disclosed are a compound or a pharmaceutically acceptable salt thereof which function as a SMARCA2/4 inhibitor, said compound having the structural formula shown in formula I. Further disclosed are a pharmaceutical composition containing...
|
|
WO/2023/246867A1 |
The present invention provides a Nav1.8 inhibitor. Specifically, the present invention provides a compound represented by formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereo...
|
|
WO/2023/243677A1 |
The present invention provides a plant disease control method having an excellent efficacy for controlling plant diseases, the method comprising treating plants or soil used for plant cultivation with a compound represented by formula (I...
|
|
WO/2023/239675A1 |
The present disclosure is related to STING agonists, pharmaceutical compositions thereof, and the use of the agonists and pharmaceutical compositions to induce a STING-mediated immune response and/or to treat diseases and disorders media...
|
|
WO/2023/231997A1 |
Provided in the present invention are a pyridazine compound represented by formula (II), and a preparation method therefor and the use thereof. Further disclosed in the present invention is the use of the compound of the present inventio...
|
|
WO/2023/223055A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
|
|
WO/2023/217989A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2023/220741A1 |
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
|
|
WO/2023/213626A1 |
The present invention relates to the use of (5S)-3-[3-( -chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl] 5-(2-chloro-4-methylbenzyl)-5,6-dihydro-4H-1,2,4-oxadiazine according to formula (I) for controlling unwanted microorganisms causing...
|
|
WO/2023/209086A1 |
The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
|
|
WO/2023/209090A1 |
The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
|
|
WO/2023/204124A1 |
The present invention addresses the problem of providing: a pyridazinone compound having excellent bactericidal/antibacterial activities and excellent safety and capable of being synthesized industrially advantageously; an agricultural a...
|
|
WO/2023/202626A1 |
The present invention provides a PRMT5 inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a solvate thereof. The present inventi...
|
